Início › Câncer de Rim (Carcinoma de Células Renais) › Texas › Houston
Ensaios clínicos de Câncer de Rim (Carcinoma de Células Renais) em Houston, TX
35 estudos para Câncer de Rim (Carcinoma de Células Renais) estão buscando participantes em locais em Houston e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RecrutandoFase 1
- NEO-811 Houston Site, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
- UT MD Anderson Cancer Center, Houston
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RecrutandoFase 1
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
RecrutandoFase 1/2
- University of Texas - MD Anderson Cancer Center, Houston
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
RecrutandoFase 2
- UT MD Anderson Cancer Center, Houston
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
RecrutandoFase 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RecrutandoFase 1/2
- MD Anderson Cancer Center, Houston
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
RecrutandoFase 2
- M D Anderson Cancer Center, Houston
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RecrutandoFase 1/2
- Texas Oncology - Gulf Coast, Houston
- University of Texas MD Anderson Cancer Center, Houston
- Texas Oncology - Gulf Coast, Houston
- e mais 1
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RecrutandoFase 1
- Md Anderson Cancer Center, Houston
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
RecrutandoFase 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
RecrutandoFase 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Houston Methodist Hospital, Houston
- Methodist Willowbrook Hospital, Houston
- e mais 1
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
RecrutandoFase 2
- MD Anderson Cancer Center, Houston
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
RecrutandoFase 2
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
RecrutandoFase 1/2
- Research Site, Houston
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
RecrutandoFase 1/2
- Houston Methodist Hospital, Houston
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
RecrutandoFase 1
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
RecrutandoFase 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
IDOV-Immune for Advanced Solid Tumors
RecrutandoFase 1
- MD Anderson Cancer Center, Houston
PET/MR for Characterization of Renal Masses (RMs)
RecrutandoEstudo observacional
- The University of Texas MD Anderson Cancer Center, Houston
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
RecrutandoFase 1/2
- MD Anderson Cancer Center, Houston
Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
RecrutandoFase 1
- UT MD Anderson, Houston
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
RecrutandoFase 1
- M D Anderson Cancer Center, Houston
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
RecrutandoFase 1/2
- MD Anderson Cancer Center, Houston
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RecrutandoFase 1
- MD Anderson Cancer Center, Houston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
RecrutandoFase 1
- University of Texas MD Anderson Cancer Center /ID# 252004, Houston
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
RecrutandoFase 2
- MD Anderson Cancer Center, Houston
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
RecrutandoFase 2
- M D Anderson Cancer Center, Houston
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
RecrutandoFase 1/2
- MD Anderson Cancer Center, Houston
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
Recrutando
- M D Anderson Cancer Center, Houston
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RecrutandoFase 1/2
- MD Anderson Cancer Center, Houston
A Study of VET3-TGI in Patients With Solid Tumors
RecrutandoFase 1
- University of Texas MD Anderson Cancer Center, Houston
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RecrutandoFase 1
- The University of Texas MD Anderson Cancer Center, Houston
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
RecrutandoFase 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RecrutandoFase 2
- MD Anderson Cancer Center-University of Texas, Houston
- Oncology Consultants P.A., Houston
Ensaios de Câncer de Rim (Carcinoma de Células Renais) em outras cidades
- New York City, NY27 estudos
- Nashville, TN23 estudos
- Dallas, TX23 estudos
- St. Louis, MO23 estudos
- Los Angeles, CA20 estudos
- Boston, MA16 estudos
- Baldwin Park, CA16 estudos
- Philadelphia, PA15 estudos
- Pittsburgh, PA15 estudos
- Queens, NY15 estudos
- Rochester, MN14 estudos
- Cleveland, OH14 estudos
Outros estudos em Houston
- Câncer de Pulmão de Não Pequenas Células145 estudos
- Câncer de Mama127 estudos
- Câncer (todos os tipos)120 estudos
- Câncer Metastático104 estudos
- Câncer Colorretal102 estudos
- Câncer de Ovário89 estudos
- Leucemia Mieloide Aguda85 estudos
- Câncer de Pulmão78 estudos
- Câncer de Próstata75 estudos
- Câncer Endometrial68 estudos
- Câncer de Pâncreas61 estudos
- Melanoma59 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 7 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.